Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
The study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among cancer patients.
Neoplasms
DRUG: Rivaroxaban 10 MG|DRUG: Rivaroxaban 20 MG|DRUG: Low-molecular-weight heparin
Incidence rate of deep venous thrombosis, the incidence of deep venous thrombosis of the legs by the systematic examinations performed at the end of the 4-week after femoral venepuncture, 4 weeks
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Number of participants with treatment-related adverse events as assessed by CTCAE v 3.0, 4 weeks
The study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among cancer patients.